Management of strictures related to pancreaticobiliary disease continues to be an area of exploration and opportunity for treating both malignant and benign disease. Dilation and stenting of strictures helps patients maintain nutrition often while undergoing neoadjuvent treatment. This web page is intended to provide an venue to share clinical data, case studies and perspectives on biliary stenting from experts in the field to educate other physicians interested in advanced pancreaticobiliary disease management.
The Role of Cholangioscopy and RFA in Pancreaticobiliary Cancer Treatment, Neil Sharma, M.D.
Dr. Sharma discusses clinical challenges of stricture management and stent obstruction with case footage and a non-surgical, extrahepatic algorithm for cholangiocarcinoma.
Interview with Professor Nagy Habib, Head of Surgery at the Hammersmith Hospital Campus of Imperial College London
His story of RFA device innovation to help patients diagnosed with pancreaticobiliary cancers and the clinical perspective.
Endoscopic Management of Hilar Cholangiocarcinoma, Clinical Evidence Overview and Case Review Video Presentation, Michel Kahaleh, M.D.
Accuracy and cost effectiveness in stricture diagnostics, and a multidisciplinary approach to palliative treatment for non-resectable disease, including stenting, RFA, and mapping with cholangioscopy.
Habib™ EndoHPB Bipolar Radiofrequency Catheter
Steps to perform partial or complete ablation of tissue in the pancreatic and biliary tracts, notable to perform endoscopic biliary drainage and decompression prior to stent placement or afterwards to clear an occluded stent.
Warning: The safety and effectiveness of biliary metal stents for use in the vascular system has not been established.
Results from case studies may vary. Results from case studies are not predictive of results in other case studies.
INDICATIONS FOR USE in the United States:
The WallFlex Biliary RX Fully Covered Stent System RMV is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms, relief of malignant biliary obstruction prior to surgery and for indwell up to 12 months in the treatment of benign biliary strictures secondary to chronic pancreatitis.
The sale, distribution, and use of the device are restricted to prescription use inaccordance with 21 CFR §801.109
• The WallFlex Biliary RX Fully Covered Stent should not be placed in strictures that cannot be dilated enough to pass the delivery system, in a perforated duct, or in very small intrahepatic ducts.
• The WallFlex Biliary RX Fully Covered Stent System RMV should not be used in patients for whom endoscopic techniques are contraindicated.
Warnings: The safety and effectiveness of the stent has not been established for indwell periods exceeding 12 months. The WallFlex Biliary RX Fully Covered Stent System RMV is for single-use only. The safety and effectiveness of the WallFlex Biliary RX Fully Covered Stent System RMV for use in the vascular system has not been established. The safety and effectiveness of the WallFlex Biliary RX Fully Covered Stent System RMV has not been established in the treatment of benign biliary anastomotic strictures in liver transplant patients and benign biliary post abdominal surgery strictures. Testing of overlapped stents has not been conducted. The stent contains nickel, which may cause an allergic reaction in individuals with nickel sensitivity.
PLEASE REFER TO THE LABELING FOR A MORE COMPLETE LIST OF WARNINGS, PRECAUTIONS AND CONTRAINDICATIONS
Using RFA for Successful Decompression of a Bile Duct Stricture Secondary to Cholangiocarcinoma, Paul R. Tarnasky, MD
Patient History The patient was a 75 year old woman diagnosed with cholangiocarcinoma in the CBD 1-1/2 years prior.